Notably, MCC expression was significantly downregulated in the following eight cancer types: cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), kidney papillary cell carcinoma (KIRP), liver cancer (LIHC), lung adenocarcinoma (LUAD), ovarian serous cystadenocarcinoma (OV), prostate cancer (PRAD), endometrial cancer (UCEC), and uterine carcinosarcoma (UCS). This evidence concerns the gene MCC and prostate carcinoma.